How Market Access Teams Work with Merlinn Insights

​​

Merlinn is a decision-support platform built on NHS primary care prescribing data. It structures, validates, and interprets large-scale public NHS datasets to help teams understand how real prescribing behavior evolves at molecule and form level, across regions and over time.

Merlinn does not recommend actions or optimize commercial outcomes. It provides a governance-safe, evidence-based view of prescribing behavior to support responsible healthcare decision-making.

​

Market access is about alignment — not acceleration

​

Market access in healthcare is not about speed. It is about alignment.

Alignment between prescribing behavior, healthcare system realities, regional variation, and long-term affordability. Decisions made by market access teams shape not only access pathways, but also sustainability across the healthcare system.

This is where Merlinn supports market access teams in a distinct and responsible way.

​

From assumptions to system-level understanding

Market access teams are often asked complex questions early in the process:

​

• Is observed uptake driven by genuine prescribing need or short-term local effects?

• How consistent is adoption across regions and care settings?

• Are differences structural, or linked to temporary constraints and behaviors?

• How does prescribing behavior evolve once initial access is granted?

​

Merlinn supports these questions by analyzing NHS primary care prescribing behavior across regions, chapters, and molecules. Large-scale public data is transformed into interpretable insight, showing how access decisions translate into real-world use within the healthcare system.

​

Seeing system behavior, not isolated outcomes

​

Rather than focusing on commercial performance indicators, Merlinn helps market access teams understand how behavior develops within the healthcare system.

Teams can observe how prescribing spreads geographically over time, where adoption is broad versus localized, how stable or fragile utilization patterns are, and how different molecules behave under similar access conditions.

This enables teams to assess whether access outcomes reflect sustainable system behavior, rather than early or temporary signals.

​

A practical example

A market access team may observe stable national prescribing levels for a molecule. Merlinn can reveal that this apparent stability is driven by a limited number of regions, while utilization in other areas remains low or volatile.

This distinction helps teams understand whether access reflects broad system adoption or localized effects — without drawing commercial conclusions or making assumptions. The value lies in interpreting behavior, not predicting outcomes.

​

Working with regional complexity at scale

​

NHS prescribing data reflects one of the most regionally complex healthcare systems in the world. For market access teams, the challenge is not lack of data but interpreting regional variation responsibly.

​

Merlinn structures, validates, and continuously updates NHS data so teams can explore prescribing behavior at national, regional, and local levels — without manual data preparation or technical overhead.

​

When new NHS data is released, it becomes available in Merlinn within hours, supporting continuity in assessment and governance discussions.

​

Supporting governance-safe decision-making

Merlinn supports governance discussions with evidence — not decisions.

​

It does not recommend pricing actions, access strategies, or tactical interventions.

​

Instead, it provides a clear, defensible evidence layer that helps market access teams:

​

• Sense-check assumptions against real prescribing behavior

• Understand regional variability in context

• Support payer and governance discussions with evidence

• Reduce uncertainty in long-term access planning

​

In healthcare, market access insight is not about optimization. It is about responsibility, transparency, and system trust.

​

Merlinn is designed to support that responsibility by making real-world prescribing behavior visible, interpretable, and usable for thoughtful market access decision-making.

​

A final thought

Market access decisions do not end at approval. Understanding how prescribing behavior evolves in practice is essential for sustaining access, managing uncertainty, and maintaining alignment with healthcare system realities.

​

If you are involved in market access, portfolio strategy, or governance discussions and would like to explore how NHS prescribing data can be interpreted more clearly and responsibly, Merlinn provides a practical starting point for that conversation.

​​

Erhan Alkan

Managing Director

Triton BIT Solutions

​​